Oncology Analytics, Inc. (OA) announced today the appointment of Dr.
Michael Baum [MB, ChB, FRCS, MD (hon), FRCR (hon)], Professor Emeritus
of Surgery and visiting Professor of Medical Humanities, University
College London, to its Distinguished Academic Advisory Board.
Michael Baum has held the chairs of surgery at Kings College London, the
Institute of Cancer Research and University College London. He has been
President of the British Oncology Association and the European Breast
Cancer Conference and chairman of the Psycho-social committee of the
National Cancer Research Institute. He has been awarded the William
McGuire prize at San Antonio Texas, the Charles Gross prize in France,
the St. Gallen prize in Switzerland, and the gold medal of the
International College of Surgeons for his research on the treatment of
Dr. Baum established the first clinical trials centers in the UK, was
one of the first to challenge the doctrine of radical matectomy, led
the first trial that demonstrated the potential of tamoxifen to prolong
life in breast cancer victims and was also the first to describe
psychometric instruments to measure quality of life in cancer sufferers.
Most recently he led the first trial to demonstrate the equivalence of a
single dose of intra-operative radiotherapy with 6 weeks of
Dr. Baum will assist OA with its ongoing critical evaluation of cancer
clinical trial design and the relative value of competing therapeutic
approaches. Dr. Baum's clinical opinions will also be available to the
thousands of oncologists whose practices OA serves. Additionally, Dr.
Baum will contribute to clinical research priorities, assist with
position papers and participate in producing OA's peer review
About Oncology Analytics, Inc.
Oncology Analytics (OA) is nationally accredited by URAC, serving
providers and healthplans through its easy-to-use MetisTM
prior authorization system and broad, guidelines compliant protocols
database, supported by expert medical oncology peer review and related
advisory services. Oncology Analytics presents treating oncologists with
the most efficacious, least toxic and most cost-responsible treatment
options, all supported by strong science and clinical data, to help them
get a "faster, better yes" in the required prior authorization processes
of payers. OA was recognized by Inc magazine's Inc 500|5000 list
as the 18th fastest growing private company in the health
sector in 2013. www.oncologyanalytics.com
[ Back To NFVZone's Homepage ]